Helio Genomics announced a strategic commercial partnership with Syneos Health, a fully integrated biopharmaceutical solutions organization. The collaboration is designed to harness Syneos Health's extensive commercialization expertise, national field deployment capabilities, and proven ability to engage healthcare providers to drive awareness and adoption of HelioLiver, Helio Genomics' blood-based test for the early detection of hepatocellular carcinoma. Syneos Health will deploy targeted field engagement, deliver tailored educational initiatives and execute integrated promotional strategies to support HelioLiver reaching hepatologists, gastroenterologists, and other providers managing high-risk populations nationwide.
This will be underpinned by the predictive and adaptive analytics capabilities of Syneos Health's AI-powered Kinetic platform, designed to connect, harmonize and streamline end-to-end commercial solutions. HelioLiver is reimbursed by Medicare at $662 per test (CPT 0333U).
